ArticlePloS one2026

TNFRSF17 as a complementary biomarker to PD-L1 for predicting the response to immunotherapy in urothelial bladder cancer.

Jiawen Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.